Delta Diagnostics develops label-free, multiplexed biosensors utilizing integrated photonics to enable real-time detection of biomolecules without the need for tagging. This technology accelerates research by at least four times and reduces the cost of ownership by a factor of five, making high-performance biosensing accessible to a broader range of researchers and developers.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional biomolecule detection methods often require labeling target molecules, which can be time-consuming, expensive, and may interfere with natural interactions. Existing label-free biosensors often compromise on sensitivity, multiplexing capabilities, or cost-effectiveness, limiting their accessibility and utility for many researchers.
Solution
Delta Diagnostics offers a label-free, multiplexed biosensing platform based on integrated photonics, enabling real-time detection of biomolecules without the need for tagging. This technology accelerates research by providing more data from precious samples and speeds up assay development workflows. The platform overcomes limitations of existing technologies by providing high sensitivity and multiplexing capabilities at a reduced cost, making high-performance biosensing accessible to a broader range of researchers and developers. The system allows scientists to study interactions between biomolecules, perform kinetics-screening for drug candidates, select high-quality antibodies, and develop rapid quantitative biomarker assays in real-time.
Target Audience
The primary target audience includes assay developers validating biomarker panels, academic researchers seeking more data from limited samples, and pharmaceutical scientists aiming to accelerate drug development.
Features
- Label-free detection of biomolecules, eliminating the need for target molecule tagging
- Multiplexed biosensing capabilities for simultaneous detection of multiple analytes
- Integrated photonics-based technology for enhanced sensitivity and accuracy
- Real-time monitoring of biomolecular interactions and kinetics
- Accelerated research workflows with >3x faster assay development
- Reduced cost of ownership compared to existing label-free biosensing technologies